Oruka Therapeutics (ORKA) news

Halozyme Therapeutics, Inc.: H.C. Wainwright raises target price to $130 from $115

H.C. Wainwright has raised its price target for Oruka Therapeutics (ORKA) to $130 from $115, maintaining a Buy rating for the stock. This upgrade follows a series of developments that have bolstered investor confidence in Oruka’s clinical pipeline and strategic partnerships. Among the most…

Oruka Therapeutics - 52-week Everlast-A data expected in December 2026

Oruka Therapeutics, Inc. is anticipated to release 52-week data for its Everlast-A program in December 2026, according to current expectations. This milestone follows ongoing clinical development efforts and represents a key step in the company’s pipeline advancement. Investors and stakeholders are…

Oruka Therapeutics - Two serious adverse events reported, neither deemed drug related

Oruka Therapeutics, Inc. has disclosed two serious adverse events in its clinical trials, according to a recent release from the company’s investor relations department. The events, which occurred during ongoing studies, were evaluated by the company’s medical and safety teams. Following a thorough…

Oruka Therapeutics announces positive week 28 data for Orka-001 from the ongoing Everlast-A trial showing deepening of responses without additional dosing

Oruka Therapeutics appoints Todd Edwards as chief commercial officer

Oruka Therapeutics has appointed L. Todd Edwards as its chief commercial officer (CCO), bringing extensive experience in the commercialization of dermatological and immunological therapies to the company. Edwards, who previously served as CCO at Arcutis Biotherapeutics, Inc., has over 25 years of…